Romark, L.C.

romark.com

Romark, L.C. is a pharmaceutical company committed to the discovery, development and commercialization of innovative small molecules for treating infectious diseases and cancers. Our people share a passion for scientific discovery and a desire to make a difference in the world's health.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights, PHARMACY MARKET

AEON BIOPHARMA TO BECOME PUBLICLY LISTED VIA MERGER WITH PRIVETERRA ACQUISITION CORP.; ACCELERATING CLINICAL DEVELOPMENT OF ABP-450

AEON Biopharma | December 14, 2022

news image

AEON Biopharma, Inc. a private clinical-stage biopharmaceutical company focused on the development of its proprietary botulinum toxin complex ABP-450 injection for therapeutic indications, and Priveterra Acquisition Corp. a special purpose acquisition company announced that they have entered into a definitive business combination agreement. Upon closing of the proposed transaction, the combined company will operate as AEON Biopharma, Inc. and is expected to list on Nasdaq under the ticker symbol...

Read More

Business Insights

FOSUN PHARMA AND INSILICO MEDICINE ANNOUNCE A STRATEGIC, AI-DRIVEN DRUG DISCOVERY AND DEVELOPMENT COLLABORATION TO JOINTLY ADVANCE MULTIPLE TARGETS

Insilico Medicine | January 18, 2022

news image

Shanghai Fosun Pharmaceutical Co., Ltd, a leading innovation-driven international healthcare group in China and Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery and development company, entered into a collaboration agreement to advance the discovery and development of drugs targeting a number of different targets globally through the use of AI technology. This strategic collaboration includes an AI-driven drug discovery research and development (...

Read More

HOW AI IS HELPING PHARMA COPE WITH SUPPLY CHAIN DISRUPTION

EPM Magazine | June 25, 2020

news image

As the Covid-19 crisis continues to unsettle global economies and business sectors worldwide, pharma companies are facing huge disruption to their supply chains and clinical research. And while research into potential Covid-19 vaccines and treatments is speeding along, the pandemic has slowed or brought to a halt clinical trials for other diseases, with organisations like Eli Lilly and other big name pharma’s’ putting the brakes on non Covid-19 trial activity. In fact,...

Read More

Business Insights, PHARMACY MARKET

ENVISION PHARMA GROUP ANNOUNCES ACQUISITION OF OKRA.AI

Envision Pharma Group | February 10, 2023

news image

Envision Pharma Group (Envision), a leading evidence-based communication services and industry-leading technology solutions provider serving biotech, pharmaceutical, and medical device companies recently announced the acquisition of OKRA.ai, a leading technology company active in the development of artificial intelligence (AI) solutions for commercialization, medical, real-world evidence and data analytics, and pricing for the life sciences and pharmaceutical industries. OKRA.ai...

Read More
news image

Business Insights, PHARMACY MARKET

AEON BIOPHARMA TO BECOME PUBLICLY LISTED VIA MERGER WITH PRIVETERRA ACQUISITION CORP.; ACCELERATING CLINICAL DEVELOPMENT OF ABP-450

AEON Biopharma | December 14, 2022

AEON Biopharma, Inc. a private clinical-stage biopharmaceutical company focused on the development of its proprietary botulinum toxin complex ABP-450 injection for therapeutic indications, and Priveterra Acquisition Corp. a special purpose acquisition company announced that they have entered into a definitive business combination agreement. Upon closing of the proposed transaction, the combined company will operate as AEON Biopharma, Inc. and is expected to list on Nasdaq under the ticker symbol...

Read More
news image

Business Insights

FOSUN PHARMA AND INSILICO MEDICINE ANNOUNCE A STRATEGIC, AI-DRIVEN DRUG DISCOVERY AND DEVELOPMENT COLLABORATION TO JOINTLY ADVANCE MULTIPLE TARGETS

Insilico Medicine | January 18, 2022

Shanghai Fosun Pharmaceutical Co., Ltd, a leading innovation-driven international healthcare group in China and Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery and development company, entered into a collaboration agreement to advance the discovery and development of drugs targeting a number of different targets globally through the use of AI technology. This strategic collaboration includes an AI-driven drug discovery research and development (...

Read More
news image

HOW AI IS HELPING PHARMA COPE WITH SUPPLY CHAIN DISRUPTION

EPM Magazine | June 25, 2020

As the Covid-19 crisis continues to unsettle global economies and business sectors worldwide, pharma companies are facing huge disruption to their supply chains and clinical research. And while research into potential Covid-19 vaccines and treatments is speeding along, the pandemic has slowed or brought to a halt clinical trials for other diseases, with organisations like Eli Lilly and other big name pharma’s’ putting the brakes on non Covid-19 trial activity. In fact,...

Read More
news image

Business Insights, PHARMACY MARKET

ENVISION PHARMA GROUP ANNOUNCES ACQUISITION OF OKRA.AI

Envision Pharma Group | February 10, 2023

Envision Pharma Group (Envision), a leading evidence-based communication services and industry-leading technology solutions provider serving biotech, pharmaceutical, and medical device companies recently announced the acquisition of OKRA.ai, a leading technology company active in the development of artificial intelligence (AI) solutions for commercialization, medical, real-world evidence and data analytics, and pricing for the life sciences and pharmaceutical industries. OKRA.ai...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us